Boston Scientific (BSX) Reports In-Line Q3 EPS, Offers Q4 Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $45.65 -4.5%
EPS Growth %: +8.0%
Financial Fact:
Net income (loss) per common share - basic: 0.17
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +8.0%
Financial Fact:
Net income (loss) per common share - basic: 0.17
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.31, in-line with the analyst estimate of $0.31. Revenue for the quarter came in at $2.22 billion versus the consensus estimate of $2.21 billion.
GUIDANCE:
Boston Scientific sees Q4 2017 EPS of $0.32-$0.35, versus the consensus of $0.34. Boston Scientific sees Q4 2017 revenue of $2.345-2.375 billion, versus the consensus of $2.33 billion.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
- ASP Isotopes holds first capital markets day, targets $300M EBITDA by 2031
- Bernstein SocGen Group Reiterates Outperform Rating on Robinhood Markets (HOOD)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
